STUDY ON COST MINIMISATION ANALYSIS OF DIFFERENT BRANDS OF MEDICATIONS PRESCRIBED IN A TERTIARY CARE HOSPITAL: AN OBSERVATIONAL STUDY

Background: Cost-Minimisation Analysis (CMA), a pharmacoeconomic evaluation method, is applicable when therapeutic equivalence between alternative interventions has been established. In such situations, comparison focuses solely on identifying the least costly alternative. The current investigation was undertaken to appraise price variation among distinct brands of commonly prescribed medicines and to determine potential cost savings achievable through cost-minimisation strategies in a hospital for tertiary care. Objective: To perform a cost-minimisation analysis of commonly prescribed medicines available in different brands in a tertiary care hospital. Methods: Over the course of six months, a prospective observational study was carried out in a tertiary care facility. A sum of 385 prescriptions from inpatient and outpatient departments were reviewed. Frequently prescribed generic medications available in multiple brands were identified for analysis. Drug prices were obtained from hospital pharmacy records and standard drug price references. Therapeutic equivalence was assumed based on identical generic composition, dosage strength, and formulation. Economic parameters calculated included cost disparity, cost ratio, percentage change in cost, mean cost, and standard deviation. Statistical analysis was performed using one-way ANOVA to assess the significance of cost differences among various brand tiers. Results: A total of 47 commonly prescribed generic drugs comprising 107 brand entries were analyzed. The study revealed considerable inter-brand price variation across several drug categories. Percentage cost variation ranged from negligible values such as nitrofurantoin (0%) and hydrocortisone sodium succinate injection (0.29%) to markedly high variations observed in paracetamol infusion (155.71%), cefuroxime axetil (126.1%), injectable paracetamol (121.25%), olanzapine (92.86%), and cefoperazone–sulbactam injection (91.69%). In multiple instances, the costliest brand was more than two to three times more expensive than the least costly alternative. Statistical analysis demonstrated a significant difference in unit costs among branded categories (p < 0.05), confirming substantial price disparities between therapeutically equivalent brands. Conclusion: The study highlights significant differences in price between various brands of the same generic medications prescribed in a tertiary care hospital. Selection of the least expensive yet therapeutically equivalent brands through cost-minimisation strategies can substantially reduce treatment costs without compromising clinical outcomes. Integration of pharmacoeconomic principles into prescribing practices, formulary decisions, and procurement policies is essential to promote rational, economical, and sustainable healthcare delivery.

Authors

Publication Details

Journal
International Journal of Drug Delivery Technology
Published
2026-11-16
DOI
https://doi.org/10.25258/ijddt.16.80s.12
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

STUDY ON COST MINIMISATION ANALYSIS OF DIFFERENT BRANDS OF MEDICATIONS PRESCRIBED IN A TERTIARY CARE HOSPITAL: AN OBSERVATIONAL STUDY

Mohammad Mohasin Pasha, Merugu Ajay, Dupati Sruthi, Adla Bhanu Shobhitha et al.
3 links
International Journal of Drug Delivery Technology
Pharmaceutical Economics and Policy
article

STUDY ON COST MINIMISATION ANALYSIS OF DIFFERENT BRANDS OF MEDICATIONS PRESCRIBED IN A TERTIARY CARE HOSPITAL: AN OBSERVATIONAL STUDY

Mohammad Mohasin Pasha, Merugu Ajay, Dupati Sruthi, Adla Bhanu Shobhitha, Bondugula Karunya Reddy
article en

Abstract

Background: Cost-Minimisation Analysis (CMA), a pharmacoeconomic evaluation method, is applicable when therapeutic equivalence between alternative interventions has been established. In such situations, comparison focuses solely on identifying the least costly alternative. The current investigation was undertaken to appraise price variation among distinct brands of commonly prescribed medicines and to determine potential cost savings achievable through cost-minimisation strategies in a hospital for tertiary care. Objective: To perform a cost-minimisation analysis of commonly prescribed medicines available in different brands in a tertiary care hospital. Methods: Over the course of six months, a prospective observational study was carried out in a tertiary care facility. A sum of 385 prescriptions from inpatient and outpatient departments were reviewed. Frequently prescribed generic medications available in multiple brands were identified for analysis. Drug prices were obtained from hospital pharmacy records and standard drug price references. Therapeutic equivalence was assumed based on identical generic composition, dosage strength, and formulation. Economic parameters calculated included cost disparity, cost ratio, percentage change in cost, mean cost, and standard deviation. Statistical analysis was performed using one-way ANOVA to assess the significance of cost differences among various brand tiers. Results: A total of 47 commonly prescribed generic drugs comprising 107 brand entries were analyzed. The study revealed considerable inter-brand price variation across several drug categories. Percentage cost variation ranged from negligible values such as nitrofurantoin (0%) and hydrocortisone sodium succinate injection (0.29%) to markedly high variations observed in paracetamol infusion (155.71%), cefuroxime axetil (126.1%), injectable paracetamol (121.25%), olanzapine (92.86%), and cefoperazone–sulbactam injection (91.69%). In multiple instances, the costliest brand was more than two to three times more expensive than the least costly alternative. Statistical analysis demonstrated a significant difference in unit costs among branded categories (p < 0.05), confirming substantial price disparities between therapeutically equivalent brands. Conclusion: The study highlights significant differences in price between various brands of the same generic medications prescribed in a tertiary care hospital. Selection of the least expensive yet therapeutically equivalent brands through cost-minimisation strategies can substantially reduce treatment costs without compromising clinical outcomes. Integration of pharmacoeconomic principles into prescribing practices, formulary decisions, and procurement policies is essential to promote rational, economical, and sustainable healthcare delivery.

International Journal of Drug Delivery TechnologyVol. 16(80s)
Good health and well-being
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon